Advancing Care in Vitiligo and Atopic Dermatitis: From Pathogenesis to Targeted Therapies

Explore vitiligo and atopic dermatitis burden and how JAK inhibitors like ruxolitinib cream and upadacitinib drive lasting skin improvement.

Welcome back to another Managed Healthcare Executive Population Health Perspectives series. In this episode titled, Clinical Impact of JAK Inhibition in Vitiligo: Efficacy, Repigmentation, and Safety Insights, Dr. Seemal Desai led the conversation about the following questions: Which inflammatory chemokines associated with melanocyte destruction are reduced with JAK inhibition? What percentage of patients achieved F-VASI75 at week 24 in the TRuE-V1 and TRuE-V2 trials? What improvements in repigmentation were observed after 52 weeks of treatment with ruxolitinib cream? What were the most commonly reported adverse events associated with ruxolitinib cream in clinical trials and how are you monitoring/managing these?

In this episode, Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream, Dr. Desai explores the following questions:

In Emerging Role of Oral JAK Inhibition in Vitiligo Management, Dr. Desai delves into the following critical questions:

This episode, titled Future Directions in Vitiligo: Emerging Therapies and Patient-Centered Care, features Dr. Desai discussing the following critical questions:

In this episode titled, ‘Understanding the Pathogenesis and Epidemiology of Vitiligo’, David Rosmarin led the conversation about the following questions:

In this episode, ‘Psychosocial Impacts and Traditional Treatment Modalities in Vitiligo,’ the expert dermatologist explored the following questions:

In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions:

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the following critical questions: